Greece produces 50% of Europe’s oncology drugs, 30% of cardio-metabolic drugs and 25% of penicillin drugs

“In a world where biomedical research, new digital technologies and Artificial Intelligence are transforming healthcare systems, strengthening cooperation between the state, industry, the academic and research community, and the innovation ecosystem is a prerequisite for sustainable growth in the healthcare sector,” Deputy Minister of Development responsible for Research and Innovation Stavros Kalafatis said while addressing an event organized by the Hellenic Association of Pharmaceutical Companies as part of the “Innovation Meets Industry” initiative under the theme “Innovation in Motion.”

He added that “the initiative deepens the dialogue around innovation in the pharmaceutical sector, highlighting the strong momentum of the Greek pharmaceutical industry and its contribution to new therapies for patients.”

“For us at the Ministry of Development,” Kalafatis noted, “Research and Innovation are key pillars supporting the country’s new productive model, investments and the creation of new jobs.”

Actions Already Underway

Kalafatis also referred to a number of initiatives already being implemented, specifically noting that:

-The National Smart Specialisation Strategy (NSRF 2021-2027) has identified Pharmaceuticals and Health Life Sciences among its eight key sectors.

-Through the Recovery and Resilience Fund, NSRF programmes and national resources, the government is supporting the development of biotechnology products, clinical research and the production of high-tech pharmaceuticals.

-Cooperation between research institutions and pharmaceutical companies is being strengthened with the aim of accelerating technology transfer and the development of innovative solutions.

-Greece is promoting the participation of domestic organizations in European and international networks such as Horizon Europe.

-Investments are being made in the education and training of young scientists required by the pharmaceutical sector.

The deputy minister also referred to the significant progress achieved by the Greek pharmaceutical ecosystem, “whose contribution during the pandemic was decisive. It provided us with the tools to protect ourselves against the coronavirus,” he stressed.

“Following the government’s investment-friendly policies over the last 6 years, Greece now produces 50% of Europe’s oncology drugs, 30% of cardio-metabolic drugs and 25% of penicillin drugs. With 45 drug factories – out of 400 in the EU – it represents 10% of European production,” the Deputy Minister of Development pointed out, adding that: “With generous incentives that we have provided, over 1.5 billion euros have been invested in the fields of drug research and production, which have led to the creation of 10 new factories and 14 new research centers.”

“We have made significant steps. We are determined to move even faster in a sector that gives the country a competitive advantage, contributes to extroversion, employment and the productive reconstruction of the country,” the Deputy Minister of Development emphasized.

Προτιμώμενη πηγή στην Google

Για να εμφανίζονται περισσότερα άρθρα της Ναυτεμπορικής στις αναζητήσεις σας εύκολα και γρήγορα, πρέπει να προσθέσετε το site στις προτιμώμενες πηγές σας. Μπορείτε να το κάνετε πηγαίνοντας εδώ.